About Bioatla (BCAB)
BioAtla, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
- USD0.68
- USD0.73
- USD0.66
- USD2.38
- -21.40%
- 11M
- 760.38k
- 1.19M
- 40M
- 0.24
- -71.20%
Stock News
4 hours ago
The government shutdown is ending. Here’s how stocks performed, and what could come next for the economy.
MarketWatch
yesterday
What Anthropic's $50 billion AI infrastructure investment means for these 3 portfolio stocks
CNBC
yesterday
'Forever layoffs' and disengagement for some, pay bumps for others: What's in store for the 2026 workplace, says new report
CNBC
yesterday
White House says October jobs and inflation data may never be released because of the shutdown
CNBC
